Tempus AI - Wikipedia Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, radiology, and depression The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM " [6][7]
Personalis Expands Tempus Strategic Collaboration to Bring Ultra . . . By combining Personalis' highly sensitive MRD testing platform with Tempus' extensive market reach, the collaboration aims to equip oncologists with a powerful new tool to detect cancer recurrence earlier and manage their patients with a more personalized approach
Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance . . . Tempus AI, Inc , a leader in artificial intelligence and precision medicine, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568) aimed at accelerating the clinical development and differentiation of an antibody drug conjugate (ADC) program in oncology
Personalis and Tempus Expand Collaboration to Biopharma Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest time points, enable the selection of targeted therapies based on ultra-comprehensive genomic